×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BBIO – bridgebio pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
09:21 am
bbio
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases [Yahoo! Finance]
Low
Report
GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases [Yahoo! Finance]
12/16
08:06 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $49.00 price target on the stock.
12/13
07:18 am
bbio
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Low
Report
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
12/3
08:13 am
bbio
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology [Yahoo! Finance]
Low
Report
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology [Yahoo! Finance]
11/29
03:58 pm
bbio
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More [Yahoo! Finance]
Neutral
Report
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More [Yahoo! Finance]
11/26
12:57 pm
bbio
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug [Yahoo! Finance]
Low
Report
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug [Yahoo! Finance]
11/25
06:26 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $45.00 to $48.00. They now have a "sector outperform" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Scotiabank from $45.00 to $48.00. They now have a "sector outperform" rating on the stock.
11/25
09:10 am
bbio
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market [Yahoo! Finance]
Medium
Report
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
07:00 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Dec 10 Filed by: Kumar Neil
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Dec 10 Filed by: Kumar Neil
12/12
07:00 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Dec 10 Filed by: Trimarchi Thomas
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Dec 10 Filed by: Trimarchi Thomas
12/12
07:00 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Dec 10 Filed by: STEPHENSON BRIAN C
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Dec 10 Filed by: STEPHENSON BRIAN C
11/25
06:14 am
bbio
Form 8-K BridgeBio Pharma, Inc. For: Nov 22
High
Report
Form 8-K BridgeBio Pharma, Inc. For: Nov 22
11/20
08:01 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: Kumar Neil
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: Kumar Neil
11/20
07:58 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: STEPHENSON BRIAN C
Low
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: STEPHENSON BRIAN C
11/19
06:16 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Kumar Neil
Medium
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Kumar Neil
11/19
06:14 pm
bbio
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Trimarchi Thomas
Medium
Report
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Trimarchi Thomas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
BridgeBio Pharma (NASDAQ: BBIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating.
26.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
TOP News Decliners
3/12
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
-16.6%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: